NCT00463203已完成2 期
Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 54
- 试验地点
- 6
- 主要终点
- progression-free survival
研究概览
简要总结
Irinotecan has demonstrated activity in malignant gliomas in multiple phase II studies. The activity is limited, with an approximately 15 % response rate and a progression-free survival of 3-5 months. Given the synergy between irinotecan and bevacizumab in colorectal cancer, and the high-level expression of vascular endothelial growth factor on malignant gliomas, one would expect synergy between bevacizumab and irinotecan against gliomas.
Recent data form a small study of 32 patients from Duke University have achieved a response rate of 62% in patients with malignant gliomas. Most included patients had glioblastomas, but this regimen may also have activity in more rare primary malignant brain tumors. The investigators therefore plan to include other primary malignant brain tumors in this study, and the clinical activity will be correlated with biomarkers and PET results of metabolic activity and blood flow. This may result in information that can be used to individualize therapy in the future.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent
- •Histological verification of primary malignant brain tumor, or grade II glioma, meningeoma or ependymoma with progression and no other treatment options (including brain stem gliomas without histological verification)
- •Recurrence or progression after standard treatment (debulking surgery of possible, radiotherapy and for grade III or IV tumors temozolomide or other chemotherapy.
- •Evidence of measurable recurrent progressive disease (CT/MRI scan)
- •An interval of at least 4 weeks between prior surgical resection and study enrollment
- •An interval of at least 4 weeks between prior radiotherapy or chemotherapy and enrollment on this protocol.
- •PS 0-2 (ECOG scale)
- •Age > 18
- •Life expectancy > 3 month
- •Normal organ function:
- •Platelets > 125 x 109/l
- •Hemoglobin >6,2 mmol/l
- •Leukocytes > 3 x 109/l
- •ACN> 1,5 x 109/l
- •ASAT or ALAT < 3 x upper normal limit
- •Bilirubin < 1,5 x upper normal limit
- •Creatinine clearance > 45 ml/min
- •APTT < normal limit
- •INR < normal limit
- •Fertile females must use oral contraceptive, IUD (intrauterine device), gestagen sustained release injection, subdermal implantation, transdermal patch or hormonal vaginal ring. This must continue at least three months after the patients is off-study. Fertile males must use preservatives
- •No sign of cerebral bleeding
排除标准
- •Radiotherapy or chemotherapy within the last 4 weeks.
- •Co-medication that may interfere with study results; e.g. immuno-suppressive agents other than corticosteroids
- •Prior VEGF-based therapy
- •Any condition (medical, social, psychological), which would prevent adequate information and follow-up
- •Any other concurrent active malignancy, except, adequately treated basal or squamous cell carcinoma of the skin, or carcinoma in situ.
- •Any significant cardiac disease (New York Heart Association Class II or greater), arrhythmia, congestive heart failure, acute myocardial infarction within 6 months or unstable angina pectoris.
- •Clinically significant peripheral vascular disease
- •Evidence of bleeding diathesis, coagulopathy or taking ASA, NSAIDs or clopidogrel
- •Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 0, anticipation of need for major surgical procedure during the curse of the study
- •Minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to day 0
- •History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 month prior to day 0
- •History of known HIV, Hepatitis B and Hepatitis C negative
- •Any ongoing infection, uncontrolled diabetes mellitus, serious non-healing wound, ulcer or bone fracture
- •Pregnancy or breast feeding
- •Requires therapeutic anti-coagulation
- •Blood pressure > 150/100 mmHG
- •Grade 2 or greater proteinuria
结局指标
主要结局
progression-free survival
时间窗: 6 months
次要结局
- Response rate - Response according to MacDonald criteria(6 months)
- Adverse event according to CTCAE 3.0(6 months)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
2 期
Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant GlioblastomasMalignant GliomasNCT00463073Rigshospitalet, Denmark32
终止
2 期
Panitumumab and Irinotecan for Malignant GliomasMalignant Glioma of BrainNCT01017653Annick Desjardins16
已完成
1 期
Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) TumorsCentral Nervous System TumorsNCT00876993Johns Hopkins All Children's Hospital26
已完成
2 期
Bevacizumab Beyond Progression (BBP)Malignant GliomaGrade 4 Malignant GliomaGliosarcomaGlioblastomaNCT01740258Duke University68
已完成
2 期
TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO StudyAdvanced Colorectal CarcinomaMetastatic Colon AdenocarcinomaMetastatic Rectal AdenocarcinomaRecurrent Colon AdenocarcinomaRecurrent Colorectal AdenocarcinomaRecurrent Rectal AdenocarcinomaStage III Colon Cancer AJCC v8Stage III Colorectal Cancer AJCC v8Stage III Rectal Cancer AJCC v8Stage IIIA Colon Cancer AJCC v8Stage IIIA Colorectal Cancer AJCC v8Stage IIIB Colorectal Cancer AJCC v8Stage IIIB Rectal Cancer AJCC v8Stage IIIC Colon Cancer AJCC v8Stage IIIC Colorectal Cancer AJCC v8Stage IV Colon Cancer AJCC v8Stage IVA Colorectal Cancer AJCC v8Stage IVA Rectal Cancer AJCC v8Stage IVB Colon Cancer AJCC v8Stage IVB Colorectal Cancer AJCC v8Stage IVB Rectal Cancer AJCC v8Stage IVC Colon Cancer AJCC v8Stage IVC Colorectal Cancer AJCC v8Stage IVC Rectal Cancer AJCC v8Unresectable Colon AdenocarcinomaUnresectable Colorectal CarcinomaUnresectable Rectal AdenocarcinomaNCT04109924Roswell Park Cancer Institute42